Measuring Synaptic Density in Parkinson's Disease with SV2A PET Imaging
Synaptic changes play a critical role in the pathogenesis and progression of PD. This study investigates the changes in synaptic density in individuals with PD by using positron emission tomography (PET) imaging with 11C-UCB-J, a recently developed PET radiotracer that binds to the synaptic vesicle glycoprotein, 2A. Contact principal investigator David Matuskey, MD for more information.
Yale Parkinson’s and REM Behavior Disorders Research Study
We are seeking patients who have been diagnosed with Parkinson’s disease in the past 10 years and persons with REM sleep behavior disorder (with or without Parkinson’s disease) to participate in a research study at the Yale School of Medicine. Our research group in Yale’s Department of Neurology, under the leadership of Dr. David Hafler is conducting a clinical research study funded by Aligning Science Against Parkinson’s (ASAP) to determine the role played by the immune system in the initiation and evolution of the pathological processes of REM sleep behavior disorder and Parkinson’s disease. Our hope is to uncover information that will ultimately allow us to design a clinical trial to use immunosuppressing medicines to prevent or slow progression of Parkinson disease. This observational, non-treatment trial is the first step.
If you decide to participate in the study, you will be invited to Yale’s clinical research unit in New Haven, Connecticut to undergo clinical assessment and for the collection of biological samples including blood, stool, and spinal fluid. In addition, you may be asked to undergo a brain scan. Please email our research coordinator, Kara Mead, or call her at 203-785-2285 if you are interested in learning more about our study.
- Mental Health & Behavioral Research, Alzheimer's DiseaseKetamine for the Treatment of Depression in Parkinson's DiseasePrincipal Investigator: Sophie E Holmes
- Diseases of the Endocrine System, Genetics - AdultA Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)Principal Investigator: Michael Schilsky
- Genetics - AdultEfficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease SubjectsPrincipal Investigator: Michael Schilsky
- Diseases of the Digestive System - Liver, Diseases of the Eye, Diseases of the Nervous SystemWilson Disease RegistryPrincipal Investigator: Michael Schilsky
Movement Disorders Labs
- Hafler LabFocussing on understanding the fundamental immunology and the pathogenesis of human autoimmune disease.
- Bamford LabIdentification of functional D2 receptors on most corticostriatal terminals assists in understanding how the striatum encodes and relays information
- Tinaz LabInvestigating the brain changes in movement disorders - especially Parkinson's disease - using imaging tools such as magnetic resonance imaging, dopamine transporter scans, and positron emission tomography.
- Biederer LabMultidisciplinary research addressing how synaptogenic adhesion proteins drive synapse formation and remodel synapses and neuronal networks.
- Zhang LabUsing single-cell technologies to understand the immune responses of the central nervous system in neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, HIV-associate neurocognitive disorders, and multiple sclerosis.
- Chandra LabExploring synaptic biology and neurodegeneration.
- DeCamilli LabStudying mechanisms underlying the dynamics and traffic of intracellular membranes, with emphasis on membrane transport reactions involved in neurotransmission.